Platform
Company
Immunology & Autoimmune
Review status
Currently under review
Pending specialist review and validation.
The DRVVT Confirm 1:1 is a confirmatory blood clotting test used as part of a lupus anticoagulant evaluation. It assesses how your plasma clots in a system that is sensitive to inhibitors that target phospholipids, which are components needed for normal clotting. This step follows an initial screen and is designed to verify that a prolonged clotting time is due to an inhibitor rather than a lack of clotting factors.
In the confirm phase, your plasma is mixed with an equal part of normal plasma and tested with added phospholipid. If the added phospholipid corrects the clotting behavior, it supports the presence of a lupus anticoagulant. The test looks at clotting function in the laboratory and does not, by itself, diagnose an autoimmune disorder.
Your clinician may order this test when antiphospholipid syndrome is suspected, when routine clotting tests are unexpectedly prolonged, or when there is a history of blood clots or certain pregnancy complications. The confirmatory step helps distinguish an inhibitor effect from a clotting factor deficiency and clarifies an abnormal screening result.
Recognizing a lupus anticoagulant can guide next steps in care, including decisions about additional testing, timing of procedures, and management during pregnancy. It can also explain why other clotting tests appear abnormal, especially if you are using or starting blood thinners.
A result within your laboratory’s reference interval suggests no laboratory evidence of a phospholipid-dependent inhibitor by this method. A result above the reference interval supports the presence of a lupus anticoagulant, particularly when the screening test is abnormal and other causes are reasonably excluded.
Medicines that affect clotting, especially anticoagulants, can interfere and lead to misleading results. If findings are unclear or do not match your clinical situation, your clinician may repeat testing when interference is minimized if safe, or order complementary tests such as mixing studies, alternative lupus anticoagulant methods, and antibody testing for anticardiolipin or anti beta two glycoprotein I. Treatment choices are based on your overall risk profile, not a single laboratory value.
Borderline or unexpected results may warrant follow up after a period of time, since transient inhibitors can occur with infections or inflammation. Discuss your medications and history with your clinician before making any changes to therapy.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Direct oral anticoagulants, heparin, and warfarin can prolong or normalize clotting assays and cause false positive or false negative results. Your clinician may adjust timing, use drug-neutralizing approaches, or defer testing when safe.
Acute thrombosis, surgery, or systemic inflammation can temporarily alter clotting tests. Testing during a stable period often gives clearer results and may reduce the chance of transient inhibitors affecting interpretation.
An underfilled citrate tube, high hematocrit, or delayed processing can skew results. Proper fill volume, prompt centrifugation, and correct storage and transport conditions help ensure an accurate measurement.
Physiologic changes in pregnancy and use of estrogen-containing therapies can influence coagulation tests and interpretation. Coordination with your obstetric or specialty team may be needed for optimal timing.
Low levels of clotting factors from inherited conditions, liver disease, or vitamin K deficiency can prolong tests and mimic an inhibitor. Additional studies may be required to separate these possibilities.
References